Agios Pharmaceuticals, Inc. (AGIO): Price and Financial Metrics

Agios Pharmaceuticals, Inc. (AGIO)

Today's Latest Price: $35.50 USD

0.22 (0.62%)

Updated Oct 20 4:00pm

Add AGIO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

AGIO Stock Summary

  • With a price/sales ratio of 13.12, Agios Pharmaceuticals Inc has a higher such ratio than 88.99% of stocks in our set.
  • With a year-over-year growth in debt of 209.35%, Agios Pharmaceuticals Inc's debt growth rate surpasses 92.57% of about US stocks.
  • As for revenue growth, note that AGIO's revenue has grown 82.88% over the past 12 months; that beats the revenue growth of 93.72% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Agios Pharmaceuticals Inc, a group of peers worth examining would be RGNX, SYRS, CNCE, DRNA, and APTX.
  • Visit AGIO's SEC page to see the company's official filings. To visit the company's web site, go to

AGIO Stock Price Chart Interactive Chart >

Price chart for AGIO

AGIO Price/Volume Stats

Current price $35.50 52-week high $56.74
Prev. close $35.28 52-week low $27.77
Day low $35.46 Volume 555,100
Day high $36.07 Avg. volume 692,396
50-day MA $37.74 Dividend yield N/A
200-day MA $44.71 Market Cap 2.45B

Agios Pharmaceuticals, Inc. (AGIO) Company Bio

Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. The company was founded in 2007 and is based in Cambridge, Massachusetts.

AGIO Latest News Stream

Event/Time News Detail
Loading, please wait...

AGIO Latest Social Stream

Loading social stream, please wait...

View Full AGIO Social Stream

Latest AGIO News From Around the Web

Below are the latest news stories about Agios Pharmaceuticals Inc that investors may wish to consider to help them evaluate AGIO as an investment opportunity.

Exelixis Cabozantinib Data, And Other News: The Good, Bad And Ugly Of Biopharma

Exelixis reports data from COSMIC-021 trial of Cabozantinib Exelixis, Inc. (EXEL) reported encouraging data from its Phase 1b clinical trial involving the combination of cabozantinib (CABOMETYX) and atezolizumab (TECENTRIQ). The data has been derived from two expansion cohorts of the trial. These two cohorts are the clear cell renal cell...

Avisol Capital Partners on Seeking Alpha | September 25, 2020

Agios Pharmaceuticals A Buy For Tibsovo, Mitapivat

Agios Pharmaceuticals (AGIO) is ramping sales of its approved cancer therapy Tibsovo quite nicely. It also has an impressive pipeline of potential therapies. Agios specializes in metabolic pathways, including developing proprietary technology to study the pathways. It has discovered targets within the pathways and develops drugs that treat those targets....

William Meyers on Seeking Alpha | September 2, 2020

Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript

With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of US Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Dr. Bruce Car, our Chief Scientific Officer will join for Q&A.

Yahoo | July 31, 2020

Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript | The Motley Fool

AGIO earnings call for the period ending June 30, 2020.

The Motley Fool | July 30, 2020

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Read More 'AGIO' Stories Here

AGIO Price Returns

1-mo -2.69%
3-mo -31.97%
6-mo -23.66%
1-year 9.16%
3-year -47.21%
5-year -42.48%
YTD -25.65%
2019 3.56%
2018 -19.35%
2017 37.00%
2016 -35.72%
2015 -42.06%

Continue Researching AGIO

Want to see what other sources are saying about Agios Pharmaceuticals Inc's financials and stock price? Try the links below:

Agios Pharmaceuticals Inc (AGIO) Stock Price | Nasdaq
Agios Pharmaceuticals Inc (AGIO) Stock Quote, History and News - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7994 seconds.